Chemical formula: C₂₈₄H₄₃₂N₈₄O₇₉S₇ Molecular mass: 6,510.051 g/mol PubChem compound: 22833874
Aprotinin is a broad spectrum protease inhibitor which has antifibrinolytic properties. By forming reversible stoichiometric enzyme-inhibitor complexes, aprotinin acts as an inhibitor of human trypsin, plasmin, plasma kallikrein and tissue kallikrein, thus inhibiting fibrinolysis.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| B02AB01 | Aprotinin | B Blood and blood forming organs → B02 Antihemorrhagics → B02A Antifibrinolytics → B02AB Proteinase inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| APROTININ Solution for injection | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
Aprotinin is an active ingredient of these brands:
Austria (AT)Brazil (BR)
Canada (CA)Croatia (HR)
Ecuador (EC)
Estonia (EE)
Finland (FI)France (FR)Hong Kong (HK)
Ireland (IE)Israel (IL)
Japan (JP)
Malta (MT)New Zealand (NZ)Poland (PL)Romania (RO)Singapore (SG)South Africa (ZA)Spain (ES)Turkey (TR)
United Kingdom (UK)United States (US)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.